

December 20, 2021  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Notice of Appointment of Corporate Officer

TOKYO, December 20, 2021 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced the approval of the appointment of a corporate officer by the Board of Directors at a meeting held on December 16, 2021.

### Appointment of Corporate Officer

The Company reorganized the Research & Development Division into the Global Development Division, and appointed Dr. Koji Fukushima as Corporate Officer, Chief Medical Officer (hereinafter referred to as "CMO"), and Head of the Global Development Division from January 1, 2022.

As obtaining profitability, the Company's most important management goal for this fiscal year, is expected, we will further promote the globalization of our business as the next goal, implementing our development strategy to become a global specialty pharmaceutical company.

Statement from Mr. Fuminori Yoshida, Symbio's President and CEO: "Steady and rapid development of brincidofovir is the key to expanding our global business, which is the cornerstone of our second inauguration. With the appointment of Dr. Fukushima, our new Corporate Officer, CMO, and Head of Research and Development, who has a wealth of clinical experience, we will build the global development system to further secure our growth trajectory."

### 1. Newly appointed Corporate Officer

Name	Title
Koji Fukushima	Corporate Officer, Chief Medical Officer and Head of Global Research and Development Division

### 2. Date of Appointment: January 1, 2022

### 3. Profile of the newly appointed Corporate Officer

March 1993	MD, Tohoku University School of Medicine
March 2000	PhD, Tohoku University Graduate School of Medicine
September 2000	Postdoctoral Fellowship, Mayo Clinic (Rochester, Minnesota, USA)
April 2006	Assistant Professor at Tohoku University as Hepatologist
September 2011	Boehringer Ingelheim Medical Adviser, Group Manager of Safety Group, Drug Safety Department
January 2014  (November 2014)	Janssen Pharmaceutical K.K, Japan Medical Affairs Leader/ Director, Infectious Disease & Vaccine  (Japan Medical Affairs Leader/ Director, Oncology & Infectious Disease & Vaccine)
May 2019	Joined Symbio Pharmaceuticals Limited as Head of Medical Affairs Dept.

#### **[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125